Investing to control infectious diseases for future generations
BioSpectrum Asia|August 2020
Be it the Ebola epidemic in 2013 or the Zika outbreak in 2015 or more recently the coronavirus COVID-19 pandemic, infectious diseases are on the rise. The World Health Organization (WHO) states that infectious diseases kill more than 17 million people a year. 22 new diseases have emerged in the last 30 years. According to the vital signs report by the Centers for Disease Control and Prevention (CDC), illnesses from mosquito, tick and flea bites have tripled during the 13 years from 2004 through 2016. What can be done to prevent and manage the infectious diseases? Let’s find out.
Ayesha Siddiqui
Investing to control infectious diseases for future generations

Infectious diseases were responsible for the largest global burden of premature death and disability until the end of the twentieth century, when that distinction passed to noncommunicable diseases. Over the previous centuries, global pandemics of infectious diseases, such as smallpox, cholera, and influenza, periodically threatened the survival of entire populations. At least as early as the late 1800s, improved living conditions (such as better sanitation and piped water supplies), particularly in high-income countries (HICs), began to drive down the infectious disease burden.

By the mid-twentieth century, safe, effective, and affordable vaccines and the increasing availability of antibiotics had further reduced the toll of infectious diseases in HICs. Not until the second half of the twentieth century did largescale efforts begin to better control infectious diseases in low- and middle-income countries (LMICs), where the infectious disease burden was greatest and highly varied. These efforts included a global commitment to immunize the world’s children against the major infections for which vaccines are available and global campaigns to control malaria and diarrheal disease. The International Health Regulations of the World Health Organization (WHO) represent a key agreement among 196 countries to implement metrics and measures to detect and control outbreaks of infectious diseases and to prevent pandemics (World Health Assembly 2005).

هذه القصة مأخوذة من طبعة August 2020 من BioSpectrum Asia.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

هذه القصة مأخوذة من طبعة August 2020 من BioSpectrum Asia.

ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.

المزيد من القصص من BIOSPECTRUM ASIA مشاهدة الكل
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
BioSpectrum Asia

Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time

US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
BioSpectrum Asia

Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers

Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
BioSpectrum Asia

Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine

Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
BioSpectrum Asia

Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis

US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Singapore designs novel gene therapy offering hope for epilepsy patients
BioSpectrum Asia

Singapore designs novel gene therapy offering hope for epilepsy patients

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Spider venom heart drug moves to clinical trials in Australia
BioSpectrum Asia

Spider venom heart drug moves to clinical trials in Australia

A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).

time-read
1 min  |
BioSpectrum Asia Nov 2024
India develops portable ultrasound scanner for sports injury diagnosis
BioSpectrum Asia

India develops portable ultrasound scanner for sports injury diagnosis

A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Integris appoints medtech veteran Probir Das as new CEO
BioSpectrum Asia

Integris appoints medtech veteran Probir Das as new CEO

Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Clarity Pharma promotes Michelle Parker to CEO
BioSpectrum Asia

Clarity Pharma promotes Michelle Parker to CEO

Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.

time-read
1 min  |
BioSpectrum Asia Nov 2024
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
BioSpectrum Asia

Dr Makoto Sugita steps in as President of Nxera Pharma Japan

Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.

time-read
1 min  |
BioSpectrum Asia Nov 2024